Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

Bibliography

• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. (2001) 2:127-137.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177-182.
   PubMed Web of Science ®Google Scholar
• MONTEMURRO F, VALABREGA G, AGLIETTA M: Trastuzumab-based combination therapy for breast cancer. Expert. Opin. Pharmacother. (2004) 5:81-96.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
   PubMed Web of Science ®Google Scholar
• MARTY M, COGNETTI F, MARANINCHI D et al.: Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. (2005) 23:4265-4274.
   PubMed Web of Science ®Google Scholar
• PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1659-1672.
   PubMed Web of Science ®Google Scholar
• ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1673-1684.
   PubMed Web of Science ®Google Scholar
• HYNES NE, LANE HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer (2005) 5:341-354.
   PubMed Web of Science ®Google Scholar
• LIU B, BERNARD B, WU JH: Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations. Proteins (2006) 65:331-346.
   PubMed Web of Science ®Google Scholar
• BASELGA J, ARTEAGA CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. (2005) 23:2445-2459.
   PubMed Web of Science ®Google Scholar
• KRAUSE DS, VAN ETTEN RA: Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. (2005) 353:172-187.
   PubMed Web of Science ®Google Scholar
• LU Y, ZI X, ZHAO Y et al.: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. (2001) 93:1852-1857.
   PubMed Web of Science ®Google Scholar
• SCHIFF R, MASSARWEH SA, SHOU J et al.: Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother. Pharmacol. (2005) 56(Suppl. 1):s10-s20.
   PubMed Web of Science ®Google Scholar
• MARTIN LA, FARMER I, JOHNSTON SR et al.: Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. (2003) 278:30458-30468.
   PubMed Web of Science ®Google Scholar
• RUSNAK DW, AFFLECK K, COCKERILL SG et al.: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. (2001) 61:7196-7203.
   PubMed Web of Science ®Google Scholar
• WOOD ER, TRUESDALE AT, MCDONALD OB et al.: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. (2004) 64:6652-6659.
   PubMed Web of Science ®Google Scholar
• KONECNY GE, PEGRAM MD, VENKATESAN N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. (2006) 66:1630-1639.
   PubMed Web of Science ®Google Scholar
• CHU I, BLACKWELL K, CHEN S et al.: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. (2005) 65:18-25.
   PubMed Web of Science ®Google Scholar
• BENCE AK, ANDERSON EB, HALEPOTA MA et al.: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs (2005) 23:39-49.
   PubMed Web of Science ®Google Scholar
• BURRIS HA 3RD, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23:5305-5313.
   PubMed Web of Science ®Google Scholar
• WILKINSON GR: Drug metabolism and variability among patients in drug response. N. Engl. J. Med. (2005) 352:2211-2221.
   PubMed Web of Science ®Google Scholar
• PANDITE L, BURRIS HA, JONES S et al.: A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004) 22:Abstract 3179.
   Google Scholar
• VERSOLA MJ, BURRIS HA, JONES S et al.: Clinical activity of GW572016 in EGF10003 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004) 22:Abstract 3047.
   Google Scholar
• SPECTOR NL, XIA W, BURRIS H 3RD et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. (2005) 23:2502-2512.
   PubMed Web of Science ®Google Scholar
• STORNIOLO AM, BURRIS H, PEGRAM M et al.: A Phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 559.
   Google Scholar
• BLACKWELL KL, BURSTEIN H, PEGRAM M et al.: Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3004.
   Google Scholar
• SPECTOR NL, BLACKWELL K, HURLEY J et al.: EGF103009, a Phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 502.
   PubMed Web of Science ®Google Scholar
• GOMEZ HL, CHAVEZ MA, DOVAL DC et al.: A Phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3046.
   Google Scholar
• GEYER CE, CAMERON D, LINDQUIST D et al.: A Phase III randomized, open label, international study comparing lapatinib and capecitabine versus capecitabine in women with refractory or advanced metastatic breast cancer (EGF 100151). ASCO Scientific Special Session: Lapatinib in Trastuzumab Resistant Breast Cancer. 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• LIN NU, CAREY LA, LIU MC et al.: Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 503.
   Google Scholar
• RAVAUD A, GARDNER J, HAWKINS R et al.: Efficacy of lapatinib in patients with high tumor EGFR expression: results of a Phase III trial in advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 4052.
   Google Scholar
• WÜLFING C, MACHIELS JP, RICHEL D et al.: A single arm, multicenter, open label, Phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4594.
   Google Scholar
• MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21:2787-2799.
   PubMed Web of Science ®Google Scholar
• ABIDOYE OO, COHEN EE, WONG SJ et al.: A Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 5568.
   Google Scholar
• KAMIO N: Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours. Virchows Arch. (1996) 428:75-83.
   PubMed Web of Science ®Google Scholar
• SHINTANI S, FUNAYAMA T, YOSHIHAMA Y et al.: Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res. (1995) 15:2623-2626.
   PubMed Web of Science ®Google Scholar
• SWANTON C, FUTREAL A, EISEN T: Her2-targeted therapies in non-small cell lung cancer. Clin. Cancer Res. (2006) 12:4377s-4383s.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
   Google Scholar
• CAPPUZZO F, HIRSCH FR, ROSSI E et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. (2005) 97:643-655.
   PubMed Web of Science ®Google Scholar
• PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
   PubMed Web of Science ®Google Scholar
• TSAO MS, SAKURADA A, CUTZ JC et al.: Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med. (2005) 353:133-144.
   Google Scholar
• ROSS HJ, BLUMENSCHEIN GR, DOWLATI A et al.: Preliminary safety results of a Phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 7099.
   Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
   PubMed Web of Science ®Google Scholar
• FIELDS AL, RINALDI DA, HENDERSON CA et al.: An open-label multicenter Phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3583.
   PubMedGoogle Scholar
• RAMANATHAN RK, BELANI CP, SINGH DA et al.: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 4010.
   Google Scholar
• LEONE F, CAVALLONI G, PIGNOCHINO Y et al.: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin. Cancer Res. (2006) 12:1680-1685.
   PubMed Web of Science ®Google Scholar
• KEEFE DL: Trastuzumab-associated cardiotoxicity. Cancer (2002) 95:1592-1600.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, BYRNE JA, HAMMOND IW et al.: Results of an analysis of cardiac function in 2812 patients treated with lapatinib. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 583.
   Google Scholar
• COHEN EE: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2006) 24:2659-2665.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, SALTZ L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. (2005) 23:5235-5246.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, DELORD JP, HALPERN A et al.: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 10:345-356.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:3238-3247.
   PubMed Web of Science ®Google Scholar
• VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. (2005) 23:3536-3544.
   PubMed Web of Science ®Google Scholar
• DUDEK AZ, KMAK KL, KOOPMEINERS J et al.: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer (2006) 51:89-96.
   PubMed Web of Science ®Google Scholar
• VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 20:719-726.
   PubMed Web of Science ®Google Scholar
• VALABREGA G, MONTEMURRO F, SAROTTO I et al.: TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene (2005) 24:3002-3010.
   PubMed Web of Science ®Google Scholar
• MONTEMURRO F, DONADIO M, CLAVAREZZA M et al.: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist (2006) 11:318-324.
   PubMed Web of Science ®Google Scholar